Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE CP versus VIGPODER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE CP versus VIGPODER.
DEPAKOTE CP vs VIGPODER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valproate increases GABA concentration in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase. It also blocks voltage-gated sodium channels and T-type calcium channels.
VIGPODER (vigabatrin) is an irreversible inhibitor of GABA transaminase, leading to increased brain levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter.
250-500 mg orally twice daily, titrated by 250 mg/day every 3-7 days; maximum 60 mg/kg/day. Target trough serum concentration: 50-100 mcg/mL.
150 mg orally twice daily with or without food.
None Documented
None Documented
Terminal elimination half-life is 9-16 hours (mean ~12 hours) in adults; prolonged in hepatic impairment, elderly, and neonates.
12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl 30–50 mL/min).
Renal: 30-50% as glucuronide conjugates, 3% as unchanged drug; fecal: minimal; less than 3% excreted in bile.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% via other routes.
Category C
Category C
Anticonvulsant
Anticonvulsant